KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 74 filers reported holding KINNATE BIOPHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,213,621 | -53.8% | 8,009,729 | 0.0% | 0.24% | -45.9% |
| Q2 2023 | $24,269,479 | -24.5% | 8,009,729 | +55.7% | 0.44% | -30.3% |
| Q1 2023 | $32,147,681 | +30.3% | 5,143,629 | +27.2% | 0.63% | +33.7% |
| Q4 2022 | $24,666,137 | -49.0% | 4,043,629 | 0.0% | 0.47% | -47.4% |
| Q3 2022 | $48,321,000 | -5.2% | 4,043,629 | 0.0% | 0.90% | -2.9% |
| Q2 2022 | $50,990,000 | +12.0% | 4,043,629 | 0.0% | 0.92% | +25.2% |
| Q1 2022 | $45,531,000 | -33.2% | 4,043,629 | +5.1% | 0.74% | -15.8% |
| Q4 2021 | $68,185,000 | -23.0% | 3,847,929 | 0.0% | 0.88% | -9.9% |
| Q3 2021 | $88,579,000 | -1.1% | 3,847,929 | 0.0% | 0.97% | +7.4% |
| Q2 2021 | $89,580,000 | -25.3% | 3,847,929 | 0.0% | 0.91% | -19.2% |
| Q1 2021 | $119,901,000 | -21.7% | 3,847,929 | 0.0% | 1.12% | -16.3% |
| Q4 2020 | $153,071,000 | – | 3,847,929 | – | 1.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |